Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Uroselective alpha-1-adrenergic receptor antagonist

Phase 3Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urinary Retention PostoperativeRecruiting

Urinary Retention PostoperativePhase 3

Recruiting

Timeline

Expected Milestones

Q4 2028

ApprovedRecruiting

Urinary Retention Postoperative

NCT07174349

Clinical

Trials by Indication[1]

Urinary Retention Postoperative1 trial

The Use of an Uroselective Alpha-1-antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

Recruiting·MMayo Clinic·Approved·NCT07174349·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Uroselective alpha-1-adrenergic receptor antagonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Uroselective alpha-1-adrenergic receptor antagonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Uroselective alpha-1-adrenergic receptor antagonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMayo Clinic

Related News